Antimicrobial Resistance (AMR) is recognised by the World Health Organisation (WHO) as an urgent global health priority affecting humans, animal health and agriculture; resulting in the organisation putting together a global action plan in 2015.
Medical technology start-up Indee Labs, partnered with the Australian National Fabrication Facility (ANFF-SA), the University of South Australia and other institutions to develop a gene delivery device that has the potential to save lives of thousands of people living with a life-threatening diseases like blood cancer.
With input and participation from many host organisations such as the Johnson & Johnson Family of Companies, Cancer Council NSW among others, Macquarie University science students are given the opportunity to have industry-based elements added to their University degree.
The Clinical Oncology Society of Australia (COSA)'s pilot implementation of the Australasian Tele-Trial Model uses tele-health or videoconferencing technology to support patients living outside major metropolitan centres to access clinical trials in their areas.
South Australian start-up Carina Biotech, born out of the Australian government-funded Cooperative Research Centre for Cell Therapy Manufacturing (CRC CTM), is developing Chimeric Antigen Receptor T cell (CAR-T) technologies to treat solid and paediatric cancers.
A collaboration between MTPConnect, CSIRO's Data61 RIBIT.net, is bringing together students and industry in the Australian life sciences sector to develop skills, broaden horizons, and deliver industry placements for the future stars of the sector.
Patient recruitment to clinical trials can often be challenging, however, there is a new smartphone and web-based platform that is helping to fill that need.
Looking to improve management and workforce skills, the AusBiotech-led Global Investment Program in Life Sciences is enhancing the capability of the Australian life sciences sector to engage with international markets. By collaborating with consortium members, AusBiotech is putting the Australian life sciences sector and its companies front and centre.
Since March 2017, Accelerating Australia has been working to advance the Australian early stage biomedical innovation ecosystem. It's 160 participants across four courses have gone on to win commercial grants, seed funding and placements in accelerator programs.
Bringing together world-class scientific and clinical research teams with Australian manufacturers and established global marketers and distributors, the Oral Health Cooperative Research Centre (CRC) has developed a vaccine to target gum disease.
16 Feb 2018 / Companies
MTPConnect took 29 Australians to the 2017 MedTech Conference in San Jose, that brought together thousands of medical technology professionals from the US and across the globe.
Genetic disorders can go undiagnosed in patients leading to people enduring lengthy and invasive tests to try and find answers. Genome.One has developed a genomic test for rare and genetic conditions to assist Australians who are searching for a diagnosis.
The SPARK Co-Lab Design team, NIMo, have been on the fast track to innovation with their wearable device for the self-management of irritable bowel disease (or Non- Invasive Monitoring).
The inaugural Bridge Program is making its mark - with an abundance of partners on board such as MSD, AbbVie, Amgen, Medical Research Commercialisation Fund (MRCF), Pfizer and QUT. Eager Australian participants networked and shared their experiences at the Bridge Program’s official launch in June 2017, Residential Training Program in October 2017, and official close in November 2017.